ReviewMolecular biology reports2026
Mechanobiology of non-small cell lung cancer: bridging tumor mechanics and therapeutic strategies.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) continues to account for the majority of lung cancer-related mortality, primarily due to disease progression and the development of resistance to conventional chemotherapy, targeted therapies, radiotherapy, and immunotherapy. While genetic and epigenetic alterations have been extensively studied, growing evidence indicates that these factors alone are insufficient to explain therapeutic failure. Recent advances highlight tumor mechanobiology as a critical regulator of cancer progression and treatment response. In NSCLC, progressive stiffening of the extracellular matrix (ECM), driven by aberrant collagen deposition, crosslinking, and cancer-associated fibroblast activation, generates biomechanical cues that profoundly influence tumor cell behavior. These mechanical signals are transduced through integrins and cytoskeletal networks, activating downstream pathways such as focal adhesion kinase, Rho/ Rho-associated coiled-coil containing protein kinase (ROCK) signaling, and the Hippo pathway effectors Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ). Sustained activation of these pathways promotes epithelial-mesenchymal transition, stemness, and immune evasion, collectively contributing to therapy resistance and tumor aggressiveness. This review provides details of current evidence linking ECM stiffness-mediated mechanotransduction to therapeutic resistance in NSCLC. Furthermore, it discusses emerging therapeutic strategies aimed at targeting tumor mechanics, including ECM normalization, inhibition of mechanosensitive signaling nodes, and cancer-associated fibroblast modulation. By integrating biomechanical regulation with molecular signaling and therapeutic perspectives, this review underscores tumor mechanics as an underappreciated but clinically relevant determinant of treatment outcome. Targeting mechanobiology-driven resistance may offer novel opportunities to enhance therapeutic efficacy and improve clinical outcomes in patients with NSCLC.
Indexed as
Identifiers
42033548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.